

DAFTAR PUSTAKA

- Abu Khait, A., & Shellman, J. 2024. Transcultural adaptation in translating measurement instruments: Challenges and learned lessons. *Int J Nurs Knowl*, 35(4): 334–344.
- Anfray, C., Arnold, B., Martin, M., Eremenco, S., Patrick, D. L., Conway, K., Acquadro, C., & ISOQOL Translation and Cultural Special Interest Group (TCA-SIG). 2018. Reflection paper on copyright, patient-reported outcome instruments and their translations. *Health Qual Life Outcomes*, 16(1): 224.
- Anthoine, D., Moret, L., Regnault, A., Sébille, V., Hardouin, J.B. 2014. Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures. *Health Qual Life Outcomes*, 12(1): 2.
- Báez-Flores, J., Rodríguez-Martín, M., & Lacal, J. 2023. The therapeutic potential of neurofibromin signaling pathways and binding partners. *Commun Biol*, 6(1): 436.
- Barton, B., Wolters, P. L., Walsh, K. S., Ullrich, N. J., Rosser, T., Tonsgard, J., Viskochil, D., Schorry, E., Klesse, L. J., Fisher, M. J., Gutmann, D. H., Packer, R. J., Korf, B., Acosta, M. T., North, K. N., Payne, J. M., & NF Clinical Trials Consortium. 2025. Psychosocial functioning and determinants of the health-related quality of life in children with neurofibromatosis type 1 and cognitive impairments. *J Neurooncol*, 174(1): 65–76.
- Basto, D. L., de Souza Vieira, G., Andrade-Losso, R. M., Almeida, P. N., Riccardi, V. M., Rozza-de-Menezes, R. E., & Cunha, K. S. 2022. Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study. *Orphanet J Rare Dis*, 17(1): 341.
- Bäzner, U., Stauss, L., Kapapa, T., Wirtz, C. R., & Pala, A. 2024. Quality of life of patients with neurofibromatosis 1-Physical disability does not necessarily result in poor mental health. *Front Neurol*, 15(1): 1432196.
- Bicudo, N.P., Germano, C.M.R., de Moraes, R.T., de Avó, L.R. da S., Ferner, R.E., Melo, D.G. 2024. Association of sociodemographic and clinical factors with the quality of life of Brazilian individuals with Neurofibromatosis type 1: a cross-sectional study. *An Bras Dermatol*, 99(4): 520–526.
- Bicudo, N.P., de Menezes Neto, B.F., da Silva de Avó, L.R., Germano, C.M.R., Melo, D.G. 2016. Quality of Life in Adults with Neurofibromatosis 1 in Brazil. *J Genet Couns*, 25(5): 1063–1074.
- Botero, V., Tomchik, S. M. 2024. Unraveling neuronal and metabolic alterations in neurofibromatosis type 1. *J Neurodev Disord*, 16(1): 49.
- Brito-Santana, L., Passos, J., Jeremias, D., Azevedo, F., Neto, D., Salgado, D. 2024. Translation and Validation of the European Portuguese Version of the Quality of Life in Neurofibromatosis 1 Patients Scale (INF1-QoL). *Sinapse*, 24(2): 62–70.
- Budiastuti, D., Bandur, A. 2018. Validitas dan Reliabilitas Penelitian. Jakarta: Mitra Wacana Media.
- Cavallo, N.D., Maggi, G., Ferraiuolo, F., Sorrentino, A., Perrotta, S., Carotenuto, M., Santangelo, G., Santoro, C. 2023. Neuropsychiatric Manifestations, Reduced Self-Esteem and Poor Quality of Life in Children and Adolescents

- with Neurofibromatosis Type 1 (NF1): The Impact of Symptom Visibility and Bullying Behavior. *Children*, 10(2): 330.
- Cavallo, N.D., Maietta, P., Perrotta, S., Moretta, P., Carotenuto, M., Esposito, M., Santangelo, G., Santoro, C. 2024. Quality of Life in Children with Neurofibromatosis Type 1: Agreement between Parents and Patients, and the Role of Disease Severity and Visibility. *Children*, 11(8): 1033.
- Choi, J., An, S., Lim, S.Y. 2022. Current concepts of neurofibromatosis type 1: pathophysiology and treatment. *Arch Craniofac Surg*, 23(1): 6–16.
- Cieza Rivera, A.M., Lobato Fuertes, C., Fernández-Villa, T., Martín Sánchez, V., Atallah, I. 2024. Impact of neurofibromatosis type 1 on quality of life using the Skindex-29 questionnaire quality of life in NF1. *Orphanet J Rare Dis*, 19(1): 85.
- Connell, J., Carlton, J., Grundy, A., Taylor Buck, E., Keetharuth, A. D., Ricketts, T., Barkham, M., Robotham, D., Rose, D., & Brazier, J. 2018. The importance of content and face validity in instrument development: lessons learnt from service users when developing the Recovering Quality of Life measure (ReQoL). *Qual Life Res*, 27(7): 1893–1902.
- Cruchinho, P., López-Franco, M. D., Capelas, M. L., Almeida, S., Bennett, P. M., Miranda da Silva, M., Teixeira, G., Nunes, E., Lucas, P., Gaspar, F., & Handovers4SafeCare. 2024. Translation, Cross-Cultural Adaptation, and Validation of Measurement Instruments: A Practical Guideline for Novice Researchers. *J Multidiscip Healthc*, 17 (1): 2701–2728.
- Dance, B., Dardare, A., Fleming, J., Siow, S.F., Schlub, T.E., Crawford, H., Saunderson, R.B., Wong, C., Berman, Y. 2024. The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1. *J Dermatol*, 51(8): 1050–1059.
- Dhaenens, B.A.E., van Dijk, S.A., Fertitta, L., Taal, W., Wolkenstein, P., Oostenbrink, R. 2024. Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex. *J Patient Rep Outcomes*, 8(1): 52.
- Dhaenens, B.A.E., Rietman, A., Husson, O., Oostenbrink, R. 2023. Health-related quality of life of children with neurofibromatosis type 1: Analysis of proxy-rated PedsQL and CHQ questionnaires. *Eur J Paediatr Neurol*, 45: 36–46.
- Doser, K., Belmonte, F., Andersen, K. K., Østergaard, J. R., Hove, H., Handrup, M. M., Ejerskov, C., Mulvihill, J. J., Winther, J. F., & Kenborg, L. 2022. School performance of children with neurofibromatosis 1: a nationwide population-based study. *Eur J Hum Genet*, 30(12): 1405–1412.
- Doser, K., Jepsen, J. R. M., Kenborg, L., Miskowiak, K. W., Albieri, V., Dalton, S. O., Krøyer, A., Hove, H., Østergaard, J. R., Johansen, C., Sørensen, S. A., Mulvihill, J., Falck Winther, J., & Bidstrup, P. E. 2024. Neurocognitive functioning in adults with neurofibromatosis type 1 - a nationwide population-based study. *Orphanet J Rare Dis*, 19(1): 441.
- Engel, L., Kosowicz, L., Bogatyreva, E., Batchelor, F., Devlin, N., Dow, B., Gilbert, A. S., Mulhern, B., Peasgood, T., & Viney, R. 2023. Face Validity of Four Preference-Weighted Quality-of-Life Measures in Residential Aged Care: A Think-Aloud Study. *Patient*, 16(6): 655–666.
- Evans, D. G. R., Kallionpää, R. A., Clementi, M., Trevisson, E., Mautner, V. F., Howell, S. J., Lewis, L., Zehou, O., Peltonen, S., Brunello, A., Harkness, E.

- F., Wolkenstein, P., & Peltonen, J. 2020. Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study. *Genet Med*, 22(2): 398–406.
- Fadhilah, A., Prabandari, Y.S., Matsuo, H., Saito, R. & Shibnuma, A. 2023. Cross-cultural adaptation and psychometric properties of the Indonesian version for quality of life among breast cancer patients. *Support Care Cancer*, 31(3): 170.
- Ferner, R.E., Thomas, M., Mercer, G., Williams, V., Leschziner, G.D., Afridi, S.K., Golding, J.F. 2017. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire. *Health Qual Life Outcomes*, 15(1): 34.
- Fleming, J., Morgan, O., Wong, C., Schlub, T.E., Berman, Y. 2023. Characterization of health concerns in people with neurofibromatosis type 1. *Mol Genet Genomic Med*, 11(1): e2077.
- Foji, S., Sanagoo, A., Nia, S.H.S., Jouybari, L. 2022. Prediction of Quality of Life Using Dermatology Life Quality Index in Iranian Patients with Neurofibromatosis Type 1. *J Iran Med Counc*, 5(4): 600–607.
- García-Ruiz, R., González-Rodríguez, A.J., Sánchez-Martínez, M.A. 2023. Neurofibromatosis type 1: Diagnostic delay in children. *Actas Dermosifiliogr*, 114(7): 694–701.
- Hamoy-Jimenez, G., Elahmar, H.A., Mendoza, M., Kim, R.H., Bril, V., Barnett, C. 2022. A cross-sectional study of gender differences in quality of life domains in patients with neurofibromatosis type 1. *Orphanet J Rare Dis*, 17(1): 40.
- Hamoy-Jimenez, G., Kim, R., Suppiah, S., Zadeh, G., Bril, V., Barnett, C. 2020. Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. *Neurooncol Adv*, 2: I141–I149.
- Heaney, A., Wilburn, J., Rouse, M., Langmead, S., Blakeley, J. O., Huson, S., & McKenna, S. P. 2020. The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas. *Mol Genet Genomic Med*, 8(12): e1530.
- Hendryadi, 2017. Validitas isi: tahap awal pengembangan kuesioner. *J Ris Manaj Bisnis Fak Ekon UNIAT*, 2(2): 169-178.
- Hernina, Karlina, Y., & Puspitasari, D. A. 2024. Gender Patterns in Indonesian: A Corpus Study of Personal Pronoun References “Ia” and “Dia”. *OKARA J Bahasa Sastra*, 18(1): 98-115.
- Huda, N., Lin, Y. K., Shaw, M. K., Hsu, Y. Y., & Chang, H. J. 2022. Psychometric properties and cross-cultural adaptation of the Indonesian version of the Brief COPE in a sample of advanced cancer patients. *PloS One*, 17(11): e0275083.
- Iasella, M. P., Ruttens, D., Hompes, D., Vandecaveye, V., Sciot, R., Deroose, C., Douchy, T., Decramer, T., Jacobs, S., Denayer, E., Van Calenbergh, F., Legius, E., & Brems, H. 2025. Close Follow-Up of Patients with Neurofibromatosis Type 1 Reduces the Incidence of Malignant Peripheral Nerve Sheath Tumour. *Cancers*, 17(8): 1306.
- International Society for Quality of Life Research (ISOQOL). 2023. ISOQOL Dictionary of Quality of Life and Health Outcomes Measurement. Milwaukee: ISOQOL.
- Kang, E., Yoon, H.M., Lee, B.H. 2021. Neurofibromatosis type i: Points to be considered by general pediatricians. *Clin Exp Pediatr*, 64(4): 149–156.

- Kenborg, L., Frederiksen, L. E., Galanakis, M., Doser, K., Nielsen, T. T., Doherty, M. A., Hove, H., Østergaard, J. R., Handrup, M. M., Ejerskov, C., Mulvihill, J. J., & Winther, J. F. 2023. Employment, occupation, and income in adults with neurofibromatosis 1 in Denmark: a population- and register-based cohort study. *Orphanet J Rare Dis*, 18(1): 346.
- Koczkowska, M., Chen, Y., Xie, J., Callens, T., Gomes, A., Wimmer, K., & Messiaen, L. M. 2023. Analysis of 200 unrelated individuals with a constitutional NF1 deep intronic pathogenic variant reveals that variants flanking the alternatively spliced NF1 exon 31 [23a] cause a classical neurofibromatosis type 1 phenotype while altering predominantly NF1 isoform type II. *Hum Genet*, 142(7): 849–861.
- Koo, M., & Yang, S.-W. 2025. Questionnaire Use and Development in Health Research. *Encyclopedia*, 5(2): 65.
- Kudari, A. 2022. Reliability of the tool: Structured knowledge questionnaires on simulation in nursing education. *J Educ Technol Health Sci*, 9(2): 55-59.
- Lalvani, S., & Brown, R. M. 2024. Neurofibromatosis Type 1: Optimizing Management with a Multidisciplinary Approach. *J Multidiscip Healthc*, 17(1): 1803–1817.
- Li, H., Zhang, H., Cao, J., Guo, D., Zhang, X., & Yao, Z. 2025. Diagnosis and treatment of pediatric arterial stenosis associated with neurofibromatosis type 1. *BMC Pediatr*, 25(1): 27.
- Listernick, R., Charrow, J. 2019. The Neurofibromatoses. In: Kang, S., Amagai, M., Bruckner, A.L., Enk, A.H., Margolis, D.J., McMichael, A.J. dan Orringer, J.S., eds. *Fitzpatrick's Dermatology*. 9th ed. New York: McGraw-Hill, pp.2465–2477.
- Loponen, N., Ylä-Outinen, H., Kallionpää, R. A., Valtanen, M., Auranen, K., Järveläinen, H., Peltonen, S., & Peltonen, J. 2024. Hypertension in NF1: A closer look at the primacy of essential hypertension versus secondary causes. *Mol Genet Genomic Med*, 12(1): e2346.
- Mahajan, A., Patvekar, M., Lote, S., Deora, M.S., Poullose, D., Gogineni, J.M., Panikar, K., Chaklader, B. 2022. A Clinico-Epidemiological Study of Neurofibromatosis Type 1 and Its Relation to Quality of Life: A Cross-Sectional Study From India. *Cureus*, 14(2): e22376.
- McKown, S., Acquadro, C., Anfray, C., Arnold, B., Eremenco, S., Giroudet, C., Martin, M., & Weiss, D. 2020. Good practices for the translation, cultural adaptation, and linguistic validation of clinician-reported outcome, observer-reported outcome, and performance outcome measures. *J Patient Rep Outcomes*, 4(1): 89.
- Mladenov, K. V., Spiro, A. S., Krajewski, K. L., Stücker, R., & Kunkel, P. 2020. Management of spinal deformities and tibial pseudarthrosis in children with neurofibromatosis type 1 (NF-1). *Childs Nerv Syst*, 36(10): 2409–2425.
- Mokkink, L. B., Elsman, E. B. M., & Terwee, C. B. 2024. COSMIN guideline for systematic reviews of patient-reported outcome measures version 2.0. *Qual Life Res*, 33(11): 2929–2939.
- Mousavinasab, S. M., Khosravi, S., & Ramezanzadeh, M. 2022. Psychometric of Physicians' Awareness, Attitudes and Performance Questionnaire about Genetic Counseling and Testing. *Int J Prev Med*, 13 (134): 1-8.

- Nutakki, K., Varni, J. W., & Swigonski, N. L. 2018. PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity. *J Neurooncol*, 137(2): 337–347.
- Ozarslan, B., Russo, T., Argenziano, G., Santoro, C., & Piccolo, V. 2021. Cutaneous Findings in Neurofibromatosis Type 1. *Cancers*, 13(3): 463
- Peduto, C., Zanobio, M., Nigro, V., Perrotta, S., Piluso, G., & Santoro, C. 2023. Neurofibromatosis Type 1: Pediatric Aspects and Review of Genotype–Phenotype Correlations. *Cancers*, 15(4): 1217.
- Qin, L., Ho, W. K. Y., & Khoo, S. 2024. The Chinese version of the physical activity questionnaire for adolescents: a psychometric validity, reliability, and invariance study. *BMC Public Health*, 24(1): 3117.
- Ribeiro, F.M., Souza, A.P., Rodrigues, L.O.C., Rezende, N.A. & Campos, M.R. 2023. Association of sociodemographic and clinical factors with the quality of life of Brazilian individuals with Neurofibromatosis type 1. *Orphanet J Rare Dis*, 18(1): 87.
- Risa, D.R., Truong, V. & Sumiati, N.T., 2024. Construct validity of Subjective Well-being by Confirmatory Factor Analysis (CFA) in Indonesian caregivers of intellectually disabled children. *J Pengukuran Psikol Pendidik Indones*, 13(1): 59-70.
- Scala, M., Schiavetti, I., Madia, F., Chelleri, C., Piccolo, G., Accogli, A., Riva, A., Salpietro, V., Bocciardi, R., Morcaldi, G., Di Duca, M., Caroli, F., Verrico, A., Milanaccio, C., Viglizzo, G., Traverso, M., Baldassari, S., Scudieri, P., Iacomino, M., ... Zara, F. 2021. Genotype-Phenotype Correlations in Neurofibromatosis Type 1: A Single-Center Cohort Study. *Cancers*, 13(8): 1879.
- Slade, A., Isa, F., Kyte, D., Pankhurst, T., Kerecuk, L., Ferguson, J., Lipkin, G., & Calvert, M. 2018. Patient reported outcome measures in rare diseases: a narrative review. *Orphanet J Rare Dis*, 13(1): 61.
- Sorrentino, U., Bellonzi, S., Mozzato, C., Brasson, V., Toldo, I., Parrozzani, R., Clementi, M., Cassina, M., & Trevisson, E. 2021. Epilepsy in NF1: Epidemiologic, Genetic, and Clinical Features. A Monocentric Retrospective Study in a Cohort of 784 Patients. *Cancers*, 13(24): 6336.
- Sousa, V.D., Rojjanasrirat, W. 2011. Translation, adaptation and validation of instruments or scales for use in cross-cultural health care research: A clear and user-friendly guideline. *J Eval Clin Pract*, 17(2): 268–274.
- Terwee, C. B., Bot, S. D., de Boer, M. R., van der Windt, D. A., Knol, D. L., Dekker, J., Bouter, L. M., & de Vet, H. C. 2007. Quality criteria were proposed for measurement properties of health status questionnaires. *J Clin Epidemiol*, 60(1): 34–42.
- Wild, D., Grove, A., Martin, M., Eremenco, S., McElroy, S., Verjee-Lorenz, A., Erikson, P., & ISPOR Task Force for Translation and Cultural Adaptation 2005. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. *Value Health*, 8(2): 94–104.
- World Health Organization. 2019. Process of Translation and Adaptation of Instruments. WHO Guidelines on Translation. Geneva: World Health Organization.

- Yoshida, Y., Ehara, Y., Koga, M. & Imafuku, S. 2022. Health-related quality of life in patients with neurofibromatosis 1 in Japan: a questionnaire survey using EQ-5D-5L. *J Dermatol*, 49(12): 1228-1232.
- Zaror, C., Bravo-Soto, G., Oliveros, M. J., Burdiles, P., Wiercioch, W., Etxeandia-Ikobaltzeta, I., Balaciano, G., Sabalet, T., Neumann, I., Schünemann, H. J., Streiner, D. L., & Brignardello-Petersen, R. 2024. Cross-cultural adaptation and validation to Spanish of the PANELVIEW instrument to evaluate the health guidelines development process. *J Clin Epidemiol*, 176(111569): 1-8.
- Zuldi Imamah, F. 2016. Phonological Adaptation Of English Loanwords To Indonesian Words In Jawa Pos Newspaper. *Language Horizon J Lang Stud*, 4(2): 86-95.